-
Product Insights
Muscle Atrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Muscle Atrophy - Drugs In Development, 2023’, provides an overview of the Muscle Atrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Muscle Atrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azelaprag in Muscle Atrophy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Azelaprag in Muscle Atrophy Drug Details: Azelaprag (BGE-105) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STMC-103H in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - STMC-103H in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.STMC-103H in Atopic Dermatitis (Atopic Eczema) Drug Details:STMC-103H is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – azelaprag
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry azelaprag Drug Details Azelaprag (AMG-986) is under development for the treatment of muscle atrophy....